Celularity (CELU) welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date ...

Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...

As part of the transition to the new administration, CMS is reviewing its coverage policies for skin substitute products.

More New Mexicans will be able to receive treatment for diabetic foot ulcers, thanks to a first-in-the-nation requirement for some health insurance plans to cover the costs. Gov. Michelle Lujan ...

April is amputation prevention awareness month. Amputation rates are increasing in The Bahamas, the Caribbean and worldwide. In the United States, 160,000 people with diabetes undergo lower extremity ...

After three years of development, a smart insole designed by researchers at the University of Malta is showing promising ...

Diabetic foot screening intervals could be extended beyond 1 year for patients at very low risk for diabetic foot complications.

An LCD is a determination by a Medicare Administrative Contractor, or MAC, whether to cover a particular service on a MAC-wide, basis. A MAC processes Medicare Part A and Part B claims for a defined ...

Our Phase 1/2a clinical trial has demonstrated that the use of this stem cell population in humans is safe and effective in treating hard to heal diabetic foot ulcers." "We are extremely pleased ...